166 related articles for article (PubMed ID: 29602013)
1. DNA methylation as an epigenetic regulator of gallbladder cancer: An overview.
Muhammad JS; Khan MR; Ghias K
Int J Surg; 2018 May; 53():178-183. PubMed ID: 29602013
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation in gallbladder cancer: Promoter methylation profiling as emergent novel biomarkers.
Tekcham DS; Tiwari PK
Asia Pac J Clin Oncol; 2016 Dec; 12(4):332-348. PubMed ID: 27385126
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.
Singh TD; Gupta S; Shrivastav BR; Tiwari PK
Gene; 2016 Feb; 576(2 Pt 2):743-52. PubMed ID: 26456195
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Biomarkers in Gallbladder Cancer.
Tiwari PK
Trends Cancer; 2020 Jul; 6(7):540-543. PubMed ID: 32291238
[TBL] [Abstract][Full Text] [Related]
5. Epigenome-Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer.
Brägelmann J; Barahona Ponce C; Marcelain K; Roessler S; Goeppert B; Gallegos I; Colombo A; Sanhueza V; Morales E; Rivera MT; de Toro G; Ortega A; Müller B; Gabler F; Scherer D; Waldenberger M; Reischl E; Boekstegers F; Garate-Calderon V; Umu SU; Rounge TB; Popanda O; Lorenzo Bermejo J
Hepatology; 2021 Jun; 73(6):2293-2310. PubMed ID: 33020926
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Downregulation of PTEN in Gallbladder Cancer.
Tekcham DS; Gupta S; Shrivastav BR; Tiwari PK
J Gastrointest Cancer; 2017 Mar; 48(1):110-116. PubMed ID: 28124240
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of
Tekcham DS; Poojary SS; Bhunia S; Barbhuiya MA; Gupta S; Shrivastav BR; Tiwari PK
Indian J Med Res; 2016 May; 143(Supplement):S82-S90. PubMed ID: 27748282
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic changes in carcinogenesis of gallbladder.
Tewari M; Agarwal A; Mishra RR; Meena RN; Shukla HS
Indian J Surg Oncol; 2013 Dec; 4(4):356-61. PubMed ID: 24426757
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of Zeste Homolog 2 (EZH2) in Malignant Progression of Gallbladder Carcinoma.
Behera G; Mitra S; Mishra TS; Purkait S
J Gastrointest Cancer; 2021 Sep; 52(3):1029-1034. PubMed ID: 33051796
[TBL] [Abstract][Full Text] [Related]
10. Dysfunction of subtelomeric methylation and telomere length in gallstone disease and gallbladder cancer patients of North Central India.
Poojary SS; Mishra G; Gupta S; Shrivastav BR; Tiwari PK
J Hepatobiliary Pancreat Sci; 2016 May; 23(5):276-82. PubMed ID: 26856965
[TBL] [Abstract][Full Text] [Related]
11. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma.
Riquelme E; Tang M; Baez S; Diaz A; Pruyas M; Wistuba II; Corvalan A
Cancer Lett; 2007 May; 250(1):100-6. PubMed ID: 17084965
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis of gallbladder cancer: An update.
Mishra SK; Kumari N; Krishnani N
Mutat Res; 2019 Nov; 816-818():111674. PubMed ID: 31330366
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA aberrations: An emerging field for gallbladder cancer management.
Chandra V; Kim JJ; Mittal B; Rai R
World J Gastroenterol; 2016 Feb; 22(5):1787-99. PubMed ID: 26855538
[TBL] [Abstract][Full Text] [Related]
14. Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease.
Sharma P; Bhunia S; Poojary SS; Tekcham DS; Barbhuiya MA; Gupta S; Shrivastav BR; Tiwari PK
Tumour Biol; 2016 Nov; 37(11):14687-14699. PubMed ID: 27623942
[TBL] [Abstract][Full Text] [Related]
15. Potential biomarkers in gallbladder cancer: present status and future directions.
Srivastava K; Srivastava A; Mittal B
Biomarkers; 2013 Feb; 18(1):1-9. PubMed ID: 22931385
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.
García P; Manterola C; Araya JC; Villaseca M; Guzmán P; Sanhueza A; Thomas M; Alvarez H; Roa JC
Mol Carcinog; 2009 Jan; 48(1):79-89. PubMed ID: 18543280
[TBL] [Abstract][Full Text] [Related]
17. c‑Jun suppresses the expression of WNT inhibitory factor 1 through transcriptional regulation and interaction with DNA methyltransferase 1 in gallbladder cancer.
Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
Mol Med Rep; 2018 Jun; 17(6):8180-8188. PubMed ID: 29693707
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Frequently Down-Regulated Phosphatidylethanolamine-Binding Protein-1 in Gallbladder Cancer.
Bharti A; Ansari MA; Tewari M; Narayan G; Singh S
Dig Dis Sci; 2024 Feb; 69(2):502-509. PubMed ID: 38135812
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic downregulation of desmin in gall bladder cancer reveals its potential role in disease progression.
Bhunia S; Barbhuiya MA; Gupta S; Shrivastava BR; Tiwari PK
Indian J Med Res; 2020 Apr; 151(4):311-318. PubMed ID: 32461394
[TBL] [Abstract][Full Text] [Related]
20. WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival.
Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
Gene; 2017 Jul; 622():42-49. PubMed ID: 28438695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
